Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
(20h)
Insulet debuts latest enhancements to popular Omnipod insulin delivery system
(23h)
Affibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection
(1d)
Chutes & Ladders—AstraZeneca adds FDA cell and gene veteran
(1d)
At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts
(1d)
Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2
(1d)
As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
(1d)
Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3
(1d)
How RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’
(1d)
Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
(2d)
BioPharma Dive
Study data convince Lundbeck to push new migraine drug forward
(18h)
Generic drugmakers gain key victory in ‘skinny label’ patent case
(18h)
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
(23h)
Alnylam, Inceptive ink AI deal potentially worth $2B
(1d)
An ADC specialist sinks on safety concerns for blood cancer drug
(1d)
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
(1d)
A Spanish biotech banks $87M to make differentiated ADCs
(2d)
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
(2d)
House bill aims to crack down on China biotech deals
(2d)
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
(2d)
Endpoints News
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more
(2w)
FDA clears Gilead's hepatitis D drug, four years after prior rejection
(2w)
GOP lawmaker asks Trump administration to curb China biotech deals
(2w)
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
(2w)
How Utah’s AI prescribing experiment is going so far
(2w)
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
(2w)
Tender offer for Recordati; Sobi's gout drug passes Phase 3 test
(2w)
Why one health AI unicorn is giving away its service for free
(2w)
Novartis says Avidity's science could apply beyond muscular dystrophies
(2w)
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
(2w)
BioSpace
ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
(11h)
Lilly and Novo face off at ADA 2026 as others seek to compete in obesity
(21h)
The next FDA commissioner must be a champion for gene therapies
(21h)
Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data
(22h)
Stakeholders want Makary’s voucher program paused, calls for FDA independence
(23h)
Surviving (and thriving with) DEI in biotech
(1d)
Massachusetts’ life sciences employment dipped last year following 14 years of growth: report
(1d)
Lilly and Boehringer roll back billions in German investments over health budget cuts
(1d)
Peptide biotech Parabilis targets up to $476M IPO
(1d)
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug
(1d)
STAT News
I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
(2h)
How the Amish think about vaccines, health care costs, and much more
(2h)
CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures
(12h)
Newer GLP-1s, pushback on research cuts, and a protest
(13h)
What stripping civil service protections for thousands of federal workers will mean for HHS
(14h)
Senior NIH official pushes MAHA strategy to skeptical ADA audience
(14h)
If Americans risk their lives fighting Ebola overseas, they deserve the right to come home
(19h)
Will Makary’s FDA voucher program survive?
(20h)
Up and down the ladder: The latest comings and goings
(21h)
Texas AG investigating energy drinks
(21h)
BioPharma Trend
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1w)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(4w)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(1mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(2mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2mo)
Drug Channels
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
(1d)
The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs
(4d)
Drugs, Discounts and Data: Crafting Sustainability in an Imperfect System
(1w)
Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx’s Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun
(1w)
PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (VIDEO)
(2w)
Protecting Gross-to-Net Performance Through Single-Channel Ecosystems
(3w)
Drug Channels News Roundup, Mid-May 2026: Flawed Launch Price Math, Rising Pharmacy Closures, Hospital Pay Realities, 340B Hospitals vs. Grantees, and a Luxury Take on Specialty Pharmacy
(3w)
340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)
(4w)
The Hidden Costs of Over-Customizing Your Hub Technology Stack
(4w)
Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point
(1mo)
European Biotechnology Magazine
ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm
(19h)
Biotechnology expert joins CDMO
(19h)
Lilly and Boehringer pause $2bn German investments over planned drug-spending curbs
(20h)
Ona Therapeutics bags $86.6m Series B for stealth ADC push
(2d)
Ingenix raises €13m to scale AI drug development engine
(3d)
3PBIOVIAN expands its mammalian capacity with an additional 2,000 L bioreactor
(3d)
IMU Biosciences secures US$53m to decode the immune system
(3d)
Abivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-off
(4d)
A fresh start for Molecular Health: technology core becomes start-up Lucera
(4d)
Greywolf reports early responses with oral ERAP1 inhibitor in solid tumours
(4d)
Drug Hunter
Brushstrokes of Biology: Cell Painting for Mechanism of Action
(19h)
tazemetostat
(1d)
acoziborole
(2d)
milsaperidone
(3d)
PF-06826647
(4d)
April 2026 Patent Gazette
(1w)
Academic-Industrial Collaboration Leads to Radical Method for Expanding CRBN-Engager SAR
(1w)
Amino Acids Cheat Sheet
(1w)
paclitaxel
(1w)
Revisiting Mitochondrial Uncoupling for Metabolic Disease
(1w)
Labiotech.EU
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(21h)
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
(1d)
Highlights of ASCO 2026: how is cancer care evolving?
(2d)
Surge in M&As driven by patent expirations
(3d)
The biggest biotech funding rounds in May 2026
(3d)
What China’s new CGT rules mean for biotech business
(4d)
Can WEE1 inhibitors finally make replication stress druggable?
(1w)
World MS Day Special: Immunic reveals new hope for progressive MS
(1w)
Lab Thread: integrating workflows to replace fragmented systems
(1w)
Are we ready for the next wave of proximity degraders?
(1w)
Bio IT World
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(2d)
Trends from the Trenches: AI-Ready Life Sciences Data
(3d)
A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs
(4d)
Immunai, AstraZeneca Expand Partnership, Rancho Biosciences Releases Multi-omics Datasets, Dotmatics AI Co-Scientist
(1w)
Insilico Medicine, Human Longevity Partner for Longevity Foundation Model
(1w)
Bio-IT World VIP Conference: Exploring Breadth vs. Depth
(1w)
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
(2w)
At Bio-IT World's 25th Anniversary, Rare Disease Takes Center Stage
(2w)
Best New Products at Bio-IT World From BioTeam, Dantech, Rancho
(2w)
Microchimerism: Lifelong Biological Connections Impacting Everyone
(3w)
GEN News
How Germinal Centers Generate Antibodies Through Noisy Rounds of Mutation and Selection
(15h)
Twin Prime Editing Enables Rapid Trait Stacking in Crops
(15h)
Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization
(16h)
A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News
(18h)
Brain-Targeted Drug Discovery Barriers Drive Deep Science Ventures and Medicines Discovery Catapult Deal
(20h)
D&D‑seq Uses Base Editing to Map DNA–Protein Interactions in Single Cells
(1d)
Novel Intracellular Pathway Identified That Protects Against Viral and Bacterial Infection
(1d)
Open Letter: In Support of Mandatory Nucleic Acid Synthesis Screening and Recordkeeping
(1d)
Experimental Adjuvant Could Strengthen Mucosal Immunity with Injectable Polio Vaccines
(1d)
Stipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies
(1d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(2mo)
Understanding High-Risk Essential Thrombocythemia
(2mo)
Son’s Decision to Donate Gave His Father a Second Chance
(2mo)
Functional Precision Medicine Advances Brain Tumor Care
(2mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(2mo)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(2mo)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(2mo)
How Honest Conversations Strengthened a Couple After Cancer
(2mo)
Cardiac Health in Cancer Survivors: A Growing Need
(2mo)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(2mo)
Contract Pharma
Why Small CDMOs Matter in Pharma
(18h)
Sanofi Inks Five-Year Pact to License Owkin’s AI Scientist K Pro for Next-Gen Biopharma Agents
(19h)
WuXi Biologics Tops Out Modular Drug Product Facility in Singapore
(21h)
Gilead Sciences, Lakefront Biotherapeutics Acquire Ouro Medicines
(21h)
The Friday Brief for June 5, 2026: CPHI Americas Unveils New Destination
(22h)
Haga Bioscience Closes $2.3M Funding Round to Commercialize Spatial Biology Tech
(1d)
Massive Bio, Optellum Partner on Early Detection, Clinical Trial Access for Lung Cancer
(1d)
Travere Therapeutics, Everest Medicines Partner to Advance Civorebrutinib
(1d)
Lonza, Stipple Bio Sign ADC Licensing Deal
(1d)
Pfizer to Leverage Chai Discovery’s AI Platform
(1d)
Pharma Times
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
(2d)
European approval enables measles protection with CSL’s immunoglobulin Privigen
(2d)
JJP Biologics reports positive interim phase 1b data for nebaprubart
(2d)
Immunotherapy boost can spare more bladder cancer patients major surgery
(2d)
Deep Science Ventures and MDC partner to accelerate brain treatments
(4d)
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
(4d)
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
(2w)
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
(2w)
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
(2w)
Pepaxti study supports use in wider myeloma population
(2w)
Medcity News
Winona Launches Menopause Research Initiative
(15h)
Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward
(15h)
The 72-Hour Hurdle: Faster Prior Authorization is Exposing Healthcare’s Broken Billing Cycle
(21h)
Why Traditional CQI Breaks Down as EMS Agencies Grow
(21h)
The Smart Way to Build the Future of Fertility Benefits
(21h)
Shifting Our Focus to Sample Sensitivity: The Metric That Deserves More Attention in Respiratory Care
(21h)
What the ‘One Nation, Overcharged’ Campaign Aims to Achieve
(1d)
Startup Secures $86M to Take On One of the Challenges for ADCs in Breast Cancer
(1d)
CereVasc Rakes In $85M Challenge Traditional Brain Shunt Surgery
(1d)
Debunked Episode 27: The Impact of an FDA Commissioner’s Departure, Insider Trading, Microdosing GLP-1s and a Win for Lower Drug Prices
(1d)
Chemical & Engineering News
C&EN weekly chemistry news quiz, June 5
(18h)
Feeding chickens pomegranate peel makes their meat juicier
(19h)
Critics call for National Priority Voucher program reform
(20h)
Policy Watch: EPA safer chemicals program gets bipartisan Senate boost
(20h)
AI firm Apoha launches with machines that feel, taste, and smell
(1d)
‘Absurd’ radical reaction keeps stereochemistry intact
(1d)
Low-cost method to get lithium from rocks could lower dependence on China
(1d)
Chemistry in Pictures: DNA’s cellular do-si-do
(2d)
Obituary: Mark Ratner
(2d)
From academic start-up to multibillion-dollar acquisition
(2d)
The Pharma Letter
Everest Medicines
(58m)
An inconvenient truth? Japan, innovation, drug pricing, MFN
(18h)
No changes to Takeda’s core financials, despite $2.5 billion legal provision
(18h)
Russia aims to have generic of one of the most expensive cystic fibrosis drugs
(20h)
Phase III data show less kidney function decline with Voyxact in IgAN
(21h)
Biogen’s salanersen gets Breakthrough Therapy designation in SMA
(21h)
Pfizer signs AI drug discovery license with Chai Discovery
(21h)
Pfizer signs AI drug discovery license with Chai Discovery
(21h)
Kairos Pharma adds NSCLC asset to portfolio
(22h)
AMR Bio contributes to US National Action Plan on combating antibiotic-resistant bacteria
(23h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(2mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(2mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(2mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(2mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(2mo)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(2mo)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(2mo)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(2mo)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(2mo)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(2mo)
MedWatch
Proposed US bill would expand security screening to investments in Chinese biotech
(20h)
Axsome secures protection for its narcolepsy drug against generic competition through 2040
(23h)
Lundbeck releases more figures from migraine study
(1d)
US diabetes conference is set to scrutinize weight-loss drugs
(1d)
Novo Nordisk set to open Czech factory following major investment
(1d)
UK approves AbbVie's cancer drug for a severely-affected group of ovarian cancer patients
(1d)
Regeneron doubles potential deal value in expanded cancer treatment collaboration
(1d)
Eli Lilly and Boehringer Ingelheim reduce major investments in Germany after new healthcare reforms
(2d)
EMA reviews Novo Nordisk drugs over possible nerve damage link
(2d)
Eli Lilly exec concerned over Trump's MFN policy: Europe risks falling behind
(2d)
In The Pipeline
The Causes of Long Covid
(1d)
Action! Action Now.
(3d)
The Current Crisis: What's Happening to Science in America
(1w)
Evaluating "Co-Scientist", a New AI Science System
(1w)
That Methyl Methacrylate Tank
(1w)
Reading the Labels on Mutant Mice
(2w)
CYA
(3w)
Stemming the AI Preprint Flood
(3w)
A Futuristic Synthesis Indeed
(3w)
What Success Can Look Like, Darn It
(3w)
Pharmaphorum
Roche develops Bundibugyo Ebola test in six days
(22h)
First human trial backs AI-designed 'universal' vaccine
(1d)
Parabilis prices IPO at an ambitious $475 million
(1d)
SCOTUS backs generic firm Hikma in skinny label dispute
(1d)
ADC Therapeutics slumps on cancer drug safety scare
(1d)
Meet Dalton, a new AI-powered drug discovery platform
(1d)
EULAR 26 hears of treatment advances in lupus
(2d)
£600m funding call opens for UK Biomedical Research Centres
(2d)
AbbVie's ovarian cancer drug Elahere gets NHS green light
(2d)
NewLimit raises $435m for liver trials, and other financings
(2d)
Drug Discovery Weekly
This week in Drug Discovery (1 June – 5 June)
(22h)
Funding earmarked for research and collaboration in England
(23h)
Marketing authorisation granted to measles therapy
(1d)
Ona raises $86.6m to advance cancer-targeting ADCs
(1d)
AI can’t replace scientists, but here’s how it can assist them
(1d)
Treatment for SLE significantly reduces disease activity
(1d)
FDA grants Orphan Drug Designation to osteosarcoma treatment
(1d)
Webinar: Decoding sensitivity and resistance to Pan-RAS(ON) inhibition
(2d)
Ingenix raises €13m to scale AI drug development model
(2d)
Could a new approach determine the future of cancer treatment?
(2d)
HIT Consultant
Leveraging Real-World Data for Proactive Protocol Design
(22h)
Alternative Funding Programs vs. In-Benefit Optimization: Designing a Sustainable Specialty Drug Strategy
(1d)
Health Catalyst to Divest Vitalware Unit for $147M to Med-Metrix
(1d)
Philips and WellSpan Health Launch 7-Year Strategic AI and Imaging Partnership
(1d)
Vida Health Partners with Instacart to Launch Category-Specific Grocery Stipends for Cardiometabolic Care
(1d)
Don’t Let Legacy Data Derail Your Health System’s Growth
(1d)
Ilant Health Secures $15M to Expand Value-Based Precision Obesity Management
(3d)
4 Critical Guardrails for Community Hospital Tech Procurement
(3d)
Rural Hospitals Are Collapsing Under Administrative Burden That AI Alone Cannot Solve
(4d)
Bridging the Diagnostics Gap: Deloitte Research Exposes Core Mismatch Between Manufacturers and Providers
(1w)
Insights: Pink Sheet
US FDA Says AI Played Supporting, Summarizing Role In Fast BLA Review
(12h)
Rare Disease Groups Tell US FDA Endpoint, Biomarker, Adcomm Reforms Needed
(12h)
Recent US FDA Ad/Promo Untitled Letters Citing More Email, Internet Issues, Less DTC TV Spots
(13h)
Replimune Met With US FDA, White House Officials Two Days Before RP1 Resubmission Announced
(15h)
Pink Sheet Podcast: SCOTUS Rules On Generic Skinny Labels, US FDA’s NPV Faces Uncertain Future
(16h)
EU Targets Patchwork Clinical Trial Consent And Recruitment Requirements
(21h)
Could Off-Label Drugs Be Used To Set New Medicine Prices In Brazil?
(21h)
EMA To Release Findings From Tavneos Data Integrity Probe
(21h)
Vumerity, Wayrilz Among New Japan Recommendations
(1d)
Stakeholders Want Clearer Eligibility Criteria For US FDA’s National Priority Voucher Program
(1d)
BioXconomy
Five essentials for pharma product launch success
(2d)
What to know about CMS ASP rules as July deadline looms
(13h)
Medable launches program to speed agentic AI use
(14h)
Speed of regulatory change challenges pharma compliance teams
(20h)
Travere buys BTK inhibitor for $1.1bn to treat kidney disease
(1d)
Cencora partners with Kite to distribute CAR T-cell therapies across the US
(1d)
Aging backwards: NewLimit raises $435m to rewrite longevity science
(1d)
Ona Therapeutics bags $86.6m to push cancer-fighting ADCs into human trials
(2d)
A reality check for AI in legal functions
(2d)
WHO moves to strengthen drug trials amid ‘attack’ on science
(2d)
BioCentury
May’s approvals bring FDA to 20 NMEs on the year
(9h)
Ona’s $86.6M venture round among Spain’s biggest for a biotech: Finance Report
(9h)
ADCs headline first-in-human development at ASCO
(9h)
Forbion welcomes McDonald from Novo, promotes two partners
(10h)
Fred Hutch’s Sylvain Simon named ‘Rising Star’ at Grand Rounds U.S. in Seattle
(1d)
Meeting sign of acting FDA leadership trying to right the ship
(1d)
Congressional concern growing over integration of Chinese, U.S. biopharma
(1d)
Servier continues M&A buildout, acquires Edgewise’s neuro programs
(1d)
Legend’s ex vivo design expertise underpins in vivo CAR T efficacy
(2d)
Science Spotlight: Microglial states as druggable nodes in CNS disease
(2d)
SCRIP
AstraZeneca Stresses Interconnected Disease Strategy In CVRM
(13h)
Deal Watch: Lilly Continues Hectic Deal Stretch Via Renal-Focused Ascidian Collab
(14h)
Finance Watch: NewLimit’s $435m Series C Keeps Mega-Round Trend Going
(15h)
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path
(19h)
Ex-MSD India Chief, PE Partnering For Bold New Pharma Play
(19h)
Brain Cancer Research: Why Shilpa Medicare’s Gate2Brain Investment Matters
(1d)
Lupeng’s Jaypirca Challenger Wins China Approval In 3L Mantle Cell Lymphoma
(1d)
Chinese Oral, Injectable GLP-1s Show Variable Efficacy, Safety Ahead Of ADA
(1d)
EULAR: Novartis Closes In On Final Approval For Cosentyx
(1d)
From Fast Follower To Innovator: Korea Capturing Global Pharma Interest
(1d)